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OBJECTIVES This study was designed to test the hypothesis that myocardial implantation of myogenic
precursor cells (MPC) loaded with iron oxide can be reliably detected in vivo by cardiac
magnetic resonance imaging (MRI).
BACKGROUND In vivo imaging of targeted catheter-based implantation of MPC into infarcted left
ventricular (LV) myocardium is unavailable.
METHODS The study was conducted in seven farm pigs (four with anterior myocardial infarction), in
which autologous MPC were injected through a percutaneous catheter allowing for LV
electromechanical mapping and guided micro-injections into normal and infarcted myocar-
dium. Cardiac MRI was used to detect implanted MPC previously loaded with iron oxide
nanoparticles.
RESULTS Magnetic resonance imaging data were compared with LV electromechanical mapping and
cross-registered pathology. All 9 injections into normal and 12 injections into locally damaged
myocardium were detected on T2-weighted spin echo and inversion-recovery true-fisp MRI
(low signal areas) with good anatomical concordance with sites of implantation on
electromechanical maps. All sites of injection were confirmed on pathology that showed in all
infarct animals iron-loaded MPC at the center and periphery of the infarct as expected from
MRI.
CONCLUSIONS Targeted catheter-based implantation of iron-loaded MPC into locally infarcted LV
myocardium is accurate and can be reliably demonstrated in vivo by cardiac MRI. The ability
to identify noninvasively intramyocardial cell implantation may be determinant for future
experimental studies designed to analyze subsequent effects of such therapy on detailed
segmental LV function. (J Am Coll Cardiol 2003;41:1841–6) © 2003 by the American
College of Cardiology Foundation
Over the last decade, several studies have used cell trans-
plantation to limit postinfarction fibrous scar formation and
subsequent congestive heart failure by grafting of myogenic
precursor cells (MPC) into left ventricular (LV) myocar-
dium (1–4). In experimental studies, MPC implanted into
ischemic damaged myocardium have generated functional
tissue (1,4). The feasibility and effectiveness of MPC
transplant into infarcted myocardium were recently demon-
strated in humans (5,6). In these studies, autologous MPC
were implanted into a postinfarct scar using direct epicardial
injections during coronary artery bypass grafting. This
approach requires sternotomy that is associated with signif-
icant morbidity and mortality. Also, it combines the use of
two distinct therapeutic procedures, which may be confus-
ing when analyzing the role of MPC transplant in the
improvement of LV function. The development of catheter-
based techniques for intramyocardial cell implantation
would represent a significant step towards the clinical
emergence of this promizing therapy. Besides, a noninvasive
in vivo imaging technique able to attest proper implantation
of MPC would be determinant for accurate analysis of
subsequent therapeutic effects. We assessed, through the use
of cardiac magnetic resonance imaging (MRI), the feasibil-
ity and accuracy of targeted catheter-based myocardial
injections of iron-loaded MPC into normal and infarcted
myocardium in pigs.
METHODS
Experimental model/cell cultures. Seven farm pigs (25 to
35 kg) were premedicated with intramuscular ketamine (15
mg/kg), anesthetized with Propofol (0.35 mg/kg intravenous
[IV] bolus, and 0.05 mg/kg/min), and ventilated. Skeletal
muscular biopsy (right sternocleidomastoid) was performed in
all animals. Immediately after biopsy, anterior myocardial
infarction was induced under deep anesthesia in four animals
by a 90-min balloon occlusion of the mid-left anterior de-
scending artery followed by reflow (6F sheath introduced in the
left carotid artery). Animals received 5,000 UI heparin and 250
mg aspirin IV and were then allowed to recover.
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Skeletal muscle–derived MPC cultures were carried out
as previously described (7,8). Briefly, muscles were mechan-
ically minced, washed, and incubated in digestion medium
(HAM F12-HEPES containing 1.5 mg/ml pronase E and
0.03% EDTA) during 40 min at 37°C. Cells were isolated
from tissue debris after wash-out, slow centrifugation, and
filtering. They were then seeded in HAM-F12 containing
15% fetal calf serum. Cell expansion was enhanced by
addition of human basal fibroblast growth factor (10 ng/ml)
and insulin-like growth factor 1 (50 ng/ml). Cultures in Cell
Factory (Nunc, Roskilde, Denmark) allowed the production
of 109 cells in four weeks. The MPC were then incubated
between 4 and 36 h with various concentrations of nano-
particles of iron oxide (Endorem, Guerbet, France) (0 to 4
mg iron/106 cells). Potential toxicity of iron oxide towards
MPC was checked either immediately, or between 4 and 20
days after incubation, using the WST-1 proliferation kit
(Roche Diagnostics, Manheim, Germany). Iron Oxide up-
take by the MPC was checked by Perls stain, and optimal
conditions were defined as 24 to 36 h incubation with 4 mg
iron/106 cells. After incubation with Endorem, MPC were
extensively washed with phosphate buffered saline, trypsinized,
and recovered in serum-free medium containing 0.5% porcine
serum albumin before catheter injection (8).
Catheter injections. Four weeks after muscular biopsy, a
nonfluoroscopic endoventricular electromechanical map-
ping was performed in all seven animals (Noga-Star, Bio-
sense Webster, Diamond Bar, California), allowing for the
detection of necrotic myocardium in infarct pigs defined as
reduced electrical (5 mV) and mechanical activity (local
shortening 5%) (9,10). This catheter is implemented by a
27-gauge needle at its extremity that enables guided micro-
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Figure 1. (A) Short-term toxicity of nanoparticles of iron oxide (Endorem) towards myogenic precursor cells (MPC) was evaluated immediately after
incubation with various Endorem concentrations (0 to 4 mg iron/106 cells) and during different incubation times (4 to 36 h). Cell viability was determined
with the WST-1 Roche Diagnostics proliferation kit (Manheim, Germany). The optical density represents mitochondrial enzymatic activity that is
proportional to the number of viable cells. There was no evidence of short-term toxicity of Endorem towards MPC. (B) Long-term toxicity of Endorem
towards MPC that were incubated with 4 mg iron/106 cells during 24 h. Cell viability was evaluated at 3- to 20-day cultures using the WST-1 kit. Results
are expressed as mean optical density  SD of two experiments performed in triplicate. Compared with control (white bars), there was no evidence of
long-term toxicity of Endorem (gray bars) towards MPC in culture. OD  optical density.
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Figure 2. (A) Left ventricular (LV) voltage map in a healthy animal in which three percutaneous catheter-based injections of iron-loaded myogenic precursor cells (MPC) were performed at the LV apex (black
dots). (B) Corresponding magnetic resonance imaging 90 min after MPC implantation (long axis and apical short axis black-blood T2-weighted turbo spin echo imaging) showing the three sites of injection
(arrows) on the four-chamber view into normal myocardium with good anatomical agreement (two sites of injection were intersected on the two-chamber view, arrows). (C) Corresponding hematoxylin (upper




















cell damage caused by the passage through the catheter and
needle has been previously evaluated by comparing cell
mortality and myogenic capacities of MPC at entry and
distal extremity of the device (8). Guided transendocardial
injections (0.4 ml each, at the concentration of 100.106
cells/ml, 3 to 5 mm into the myocardium) were performed
at three different locations in healthy pigs and three loca-
tions within the ischemic tissue (one in the center, and two
in the periphery) in the four infarct animals. Pigs were then
transported to MRI facilities.
MRI. Ninety minutes after cell grafting, cardiac MRI (1.5
T Siemens Symphony, Erlangen, Germany) was performed
in anesthetized animals in the right antecubital position
with electrocardiographic gating and short breath-hold
acquisitions. A flexible cardiac phased-array coil was
wrapped around the chest for signal acquisition. The LV
long axis was localized. For detection of implanted cells,
single-phase black-blood T1- and T2-weighted turbo spin
echo MRI was performed in the apical four-chamber and
two-chamber views and in a series of six LV short-axis slices
from base to apex. Imaging parameters were typically: field
of view 280 mm; repetition time 2RR intervals; echo time
25 ms for T1 and 65 ms for T2; image matrix 256  160;
slice thickness 6 mm. For infarct size imaging, a single-
phase two-dimensional inversion-recovery true-fisp (steady-
state free precession, ssfp) pulse sequence (field of view 280
mm; inversion time 200 to 280 ms, slice thickness 6 mm)
was acquired in the same views 15 min after gadolinium-
enhanced diethlenetriaminepentaacetic acid (Gd-DTPA)
injection (0.1 mM IV).
Pathology. Pigs were euthanized under deep anesthesia
with IV potassium chloride 3 h after cell injections for
pathology. The heart was excised, and the LV was cut from
base to apex into six 6 mm-thick short-axis slices for
cross-registration with MRI. The junction between the
right ventricular free wall and the inferior septum was used
as a landmark, and myocardial segments were numbered
from 1 to 17 according to the recommendations of the
American Heart Association for cross-registration between
imaging and pathology (12). Myocardial segments in which
injections were performed, as well as remote tissue used for
control, were thin cut and stained with hematoxylin-eosin
and Perls stain.
The animals were used in accordance with the Guide for
the Care and Use of Laboratory Animals (DHHS publ. No.
NIH 85-23, revised 1996, Office of Science and Health
Reports, Bethesda, Maryland).
RESULTS
In vitro cell viability. There was no immediate toxicity of
iron oxide towards MPC (Fig. 1A), nor in cultures up to 20
days (Fig. 1B). We have recently shown that cell passage
through the catheter was not associated with significant cell
mortality (8).
Accuracy of percutaneous guided micro-injections. In
healthy animals, LV maps showed normal electrical and
mechanical activity. All nine injections within normal myo-
cardium were detected on T2-weighted spin echo MRI as
low signal areas (iron oxide) (Figs. 2A and 2B) (Table 1).
On pathology, all sites of injection were found and corre-
sponded to cross-registered low signal areas by MRI. Perls
stain revealed a huge number of implanted MPC that were
loaded with iron and organized as densely packed mono-
nucleated myoblasts (Fig. 2C). There was no visible lesion
in adjacent myocardium and no MPC in remote myocar-
dium either by MRI or on Perls stain.
In the four infarct pigs, LV maps showed dramatically
reduced electrical and mechanical activity in the anterior
wall. Iron-loaded cell injections into the infarct region were
all detected by T2-weighted spin echo MRI. Fifteen min-
utes after Gd-DTPA, inversion-recovery true-fisp MRI
showed in all animals a delayed hyperenhancement contain-
ing three distinct low signal regions (Figs. 3A and 3B). All
infarcts were located in the apical interventricular septum
and represented 6.6  2.1% of total LV myocardial area by
planimetry on MRI. Overall, the 12 sites of injection were
found by MRI within the hyperenhanced infarcted region
(Table 1). There was a nice agreement with cross-registered
pathology that showed in all animals the presence of
iron-loaded MPC at the center and periphery of the
infarcted tissue as expected from MRI (Fig. 3C).
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The 4 infarct animals had 1 injection
in the center and 2 at the
periphery of the infarct
3 apical septum
5 3 apical septum
6 1 apical septum, 1 mid-septum,
1 apex
7 3 apical septum
Electromechanical maps and MRI were visually assessed by two independent observers blinded to each other’s data.
MRI  magnetic resonance imaging.
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Figure 3. (A) Left ventricular voltage map in an infarct animal in which three percutaneous catheter-based injections of iron-loaded myogenic precursor cells (MPC) were performed into locally damaged
myocardium (one in the center and two at the periphery, black dots). (B) Corresponding magnetic resonance imaging 90 min after MPC implantation (long axis black-blood T2 turbo spin echo imaging,
upper panel; inversion-recovery true-fisp in the same view, lower panel) showing three sites of injection (arrows) into hyperenhanced damaged tissue with nice anatomical agreement. (C) Corresponding





















The main results of the study showed: 1) sites of implan-
tation of MPC loaded with iron oxide can be reliably
detected in vivo by cardiac MRI; and 2) precise targeted
catheter-based implantation of MPC into locally infarcted
myocardium is feasible and accurate.
So far, only pathology has enabled identification of the
integration of recently implanted cells into LV myocardium
(13,14). The demonstration that cardiac MRI is accurate for
noninvasive in vivo identification of iron-loaded cell im-
plantation may be determinant for future experimental
studies, particularly for accurate interpretation of follow-up
functional studies. Potential effects of implanted cells on
subsequent recovery of LV function can be analyzed accu-
rately, provided one can make sure that cells were properly
implanted at targeted locations within ischemic myocar-
dium. Indeed, MRI offers the unique opportunity to con-
firm in vivo targeted myocardial implantations of MPC
without the need for sacrifice of the animals. All sites of
implantation were accurately identified by MRI and further
confirmed by pathology with good anatomical agreement.
At utilized concentrations, iron consistently generates sus-
ceptibility artifact that represents the basis for signal detec-
tion by MRI. Implanted cells appear as low signal area on
T2-weighted images, and sites of injection are also clearly
seen within infarcted myocardium on delayed contrast-
enhanced MRI.
This work also demonstrates that percutaneous catheter-
based delivery of MPC into locally infarcted myocardium is
accurate and complements recent studies that have de-
scribed intramyocardial catheter-based injection of plasmid
(15), adenovirus (16), or more recently bone marrow cells in
pigs (17) or patients with ischemic heart disease (18).
Study limitations. The contrast in the image relies on a
susceptibility artifact, which implies that there is no linear
relationship between the intensity of the signal and the
number of implanted cells. Therefore, the size and trans-
mural distribution of the injection cannot be accurately
assessed. Although we have previously demonstrated that
cell viability is preserved after up to two weeks when
implanted cells are recovered from the implanted tissue 3 h
after injections (8), future studies are warranted to deter-
mine long-term viability, structural and architectural orga-
nization, and functional capacity of implanted cells. To
date, there are no data about the potential toxicity of direct
injections of iron-loaded cells into human myocardium,
therefore, this method is not suitable for use in patients.
CONCLUSIONS
After myocardial infarction, precise targeted catheter-based
implantation of MPC into locally infarcted myocardium is
feasible and accurate and can be reliably and noninvasively
identified in vivo by cardiac MRI.
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